Get the Stockscreener App
36.18
0.88%
-0.32
After Hours:
36.18
Royalty Pharma Plc stock is traded at $36.18, with a volume of 4.03M.
It is down -0.88% in the last 24 hours and down -3.73% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$36.50
Open:
$36.44
24h Volume:
4.03M
Relative Volume:
1.11
Market Cap:
$15.64B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
15.73
EPS:
2.3
Net Cash Flow:
$827.02M
1W Performance:
-1.31%
1M Performance:
-3.73%
6M Performance:
+10.47%
1Y Performance:
+28.94%
1-Day Range:
$36.14
$36.76
1-Week Range:
$34.08
$37.28
52-Week Range:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.18 | 15.48B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.55 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.31 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.83 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
762.89 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.93 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Nomura Holdings Inc. Buys New Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma and Deloitte Release Landmark Report on Biopharma Royalty Market Insights and Trends - Quiver Quantitative
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market - MarketScreener
87% of Pharma Leaders Embrace Royalty Funding: Royalty Pharma's Groundbreaking Industry Study Reveals Shift - Stock Titan
Alliancebernstein L.P. Acquires 86,873 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Acquired by Uniplan Investment Counsel Inc. - MarketBeat
Eventide Asset Management LLC Acquires 56,419 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cutter Capital Management LP Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Panagora Asset Management Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma’s $2 Billion Debt Raise Could Be a Game Changer for RPRX - simplywall.st
Baird Financial Group Inc. Cuts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Amundi Cuts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc likely to announce a buyback2025 Price Targets & AI Enhanced Trade Execution Alerts - 뉴스영
Punch & Associates Investment Management Inc. Purchases 101,390 Shares of Royalty Pharma PLC $RPRX - MarketBeat
AQR Capital Management LLC Acquires 704,414 Shares of Royalty Pharma PLC $RPRX - MarketBeat
AlTi Global Inc. Lowers Holdings in Royalty Pharma PLC $RPRX - MarketBeat
What is the long term forecast for Royalty Pharma plc stock2025 Support & Resistance & AI Driven Price Forecasts - beatles.ru
Is Royalty Pharma plc stock technically oversoldJuly 2025 Fed Impact & Free High Accuracy Swing Entry Alerts - beatles.ru
Royalty Pharma PLC $RPRX Holdings Cut by Adage Capital Partners GP L.L.C. - MarketBeat
Evergreen Capital Management LLC Has $453,000 Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc benefit from AI trends2025 Price Momentum & Growth Focused Stock Pick Reports - 강소기업뉴스
Walleye Capital LLC Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by BNP Paribas Financial Markets - MarketBeat
Royalty Pharma prices $2B senior unsecured notes - MSN
Canada Pension Plan Investment Board Sells 151,617 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Can technical indicators confirm Royalty Pharma plc’s reversalTrade Risk Report & Free High Return Stock Watch Alerts - Newser
How to interpret RSI for Royalty Pharma plc stockMarket Movers & Risk Controlled Stock Alerts - Newser
Ieq Capital LLC Boosts Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
What MACD and RSI say about Royalty Pharma plcWeekly Market Outlook & Precise Buy Zone Tips - Newser
Will breakout in Royalty Pharma plc lead to full recoveryTrade Entry Summary & Community Verified Watchlist Alerts - Newser
Royalty Pharma PLC $RPRX Shares Bought by American Century Companies Inc. - MarketBeat
Is Royalty Pharma plc gaining market shareEarnings Overview Report & Growth Focused Stock Reports - خودرو بانک
strategies to average down on royalty pharma plcJuly 2025 Gainers & Free Real-Time Volume Trigger Notifications - Newser
Applying sector rotation models to Royalty Pharma plc2025 Price Targets & Safe Entry Zone Tips - Newser
Will Royalty Pharma plc continue its uptrend2025 Volatility Report & Fast Exit and Entry Trade Guides - Newser
Applying Wyckoff theory to Royalty Pharma plc stockJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
Royalty Pharma PLC $RPRX Shares Purchased by OMERS ADMINISTRATION Corp - MarketBeat
GMT Capital Corp Has $74.01 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Strategies to average down on Royalty Pharma plcGap Up & Breakout Confirmation Trade Signals - Newser
Intraday pattern recognizer results for Royalty Pharma plcPortfolio Performance Report & AI Based Trade Execution Alerts - Newser
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - The Manila Times
Leading Biopharma Royalty Investor Royalty Pharma to Join Morgan Stanley Healthcare Conference Sept 9 - Stock Titan
Magnetar Financial LLC Buys Shares of 161,496 Royalty Pharma PLC $RPRX - MarketBeat
What does recent volatility data suggest for Royalty Pharma plc2025 Geopolitical Influence & Community Verified Trade Signals - Newser
Royalty Pharma plc stock outlook for YEARDollar Strength & Low Drawdown Momentum Trade Ideas - Newser
Royalty Pharma plc stock prediction for this weekJuly 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):